This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high pho…

Glioma, Recurrent High GradeGrade 4 Malignant Glioma

~Estimated

~$10 – $7,500

Nader SanaiNCT07784985

Phase 1

Targeting Myeloid-Derived Suppressor Cells in Patients With Recurrent/Progressive Grade 4 Glioma: Phase 1 Trial of Sitagliptin

Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or …

GliomaGlioblastomaRecurrent Glioma+2 more

~Estimated

~$10 – $7,500

Kailin Yang, MD, PhDNCT07541781